The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Nivolumab in patients with DNA mismatch repair-deficient/microsatellite instability-high (dMMR/MSI-H) metastatic colorectal cancer (mCRC): Long-term survival according to prior line of treatment from CheckMate-142.
 
Michael J. Overman
Consulting or Advisory Role - Bristol-Myers Squibb; Merrimack; Roche/Genentech
Research Funding - Amgen; Bristol-Myers Squibb; Celgene; MedImmune; Merck; Roche
 
Francesca Bergamo
No Relationships to Disclose
 
Raymond S. McDermott
Honoraria - Astellas Pharma; Bayer; Bristol-Myers Squibb; Janssen; Merck Sharp & Dohme; Novartis; Pfizer; Sanofi
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Janssen (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Pfizer
 
Massimo Aglietta
Honoraria - Bristol-Myers Squibb
Consulting or Advisory Role - Bristol-Myers Squibb
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Franklin Chen
Honoraria - Celgene
 
Fabio Gelsomino
No Relationships to Disclose
 
Mark Wong
Consulting or Advisory Role - Baxalta
Speakers' Bureau - Sirtex Medical
Travel, Accommodations, Expenses - MSD
 
Michael Morse
Stock and Other Ownership Interests - PhytoChem
Honoraria - Astellas Pharma; Bayer; Boehringer Ingelheim; EMD Serono; Etubics; Genentech/Roche; Ipsen; Lexicon; Merrimack; Novartis; Onyx; Regeneron; Sanofi; Taiho Pharmaceutical
Speakers' Bureau - Celgene; Genentech/Roche; Novartis; Taiho Pharmaceutical
Research Funding - Advanced Accelerator Applications (Inst); AlphaVax (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Lexicon (Inst); MedImmune (Inst); Merck (Inst); Onyx (Inst); Precision Biologics (Inst)
 
Eric Van Cutsem
Research Funding - amgen (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Celgene (Inst); Ipsen (Inst); Lilly (Inst); Merck (Inst); Merck KGaA (Inst); Novartis (Inst); Roche (Inst); Sanofi (Inst); SERVIER (Inst)
 
Alain Hendlisz
Research Funding - Bayer (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Bayer; Roche
 
Bart Neyns
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Merck; Novartis
Speakers' Bureau - Novartis
Research Funding - Novartis; Pfizer
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; Novartis; Pfizer; Roche
 
Rebecca Anne Moss
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
Honoraria - Bayer
Consulting or Advisory Role - Taiho Pharmaceutical
 
Huanyu Zhao
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb; GlaxoSmithKline
 
Z. Alexander Cao
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb; Novartis
Patents, Royalties, Other Intellectual Property - Novartis
 
Shital Kamble
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
 
Scott Kopetz
Stock and Other Ownership Interests - MolecularMatch; Navire
Consulting or Advisory Role - Amgen; Array BioPharma; Bayer; EMD Serono; Genentech; Guardant Health (Inst); Karyopharm Therapeutics; Merck; Roche; Symphony Evolution
Research Funding - Amgen (Inst); Array BioPharma (Inst); Biocartis (Inst); EMD Serono (Inst); Genentech/Roche (Inst); Guardant Health (Inst); MedImmune (Inst); Novartis (Inst); Sanofi (Inst)
 
Thierry Andre
Honoraria - Baxter; BAYER; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Lilly; MSD Oncology; Novartis; Roche/Genentech; Sanofi; SERVIER; Xbiotech
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; HalioDX; MSD Oncology; Mundipharma; Roche/Genentech; SERVIER
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; Roche/Genentech